Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BTZI - The Bots team will test the power of AI with end-to-end solutions through guided hands-on labs or as a development sandbox. Test, prototype, and deploy our own applications and models against the latest and greatest that NVIDIA has to offer through NVIDIA LaunchPad platform.
https://finance.yahoo.com/news/bots-inc-embarks-advanced-ai-081700886.html
$SMME News: SmartMetric Says the Imminent Release of Its Biometric Fingerprint Activated Credit Card Will Provide Massive Increased Protection for Card Users and Card Issuing Banks
NEW YORK--(BUSINESS WIRE)-- SmartMetric, Inc. (OTC: SMME) reports that the SmartMetric Gen 4 Biometric Fingerprint Card has been developed to meet the specific demand of the credit card industry and credit card users for enhanced credit card security. The card has an in-the-card a nano fingerprint scanner that is used to recognize the card holders fingerprint and in on a fingerprint match, instantly turn on the card.
“The mass market version of the SmartMetric Gen 4 biometric credit card is now under manufacture following the successful testing of the cards internal operating system on the new card platform," said Chaya Hendrick.
Reports on credit card fraud are continuing to show an exponential growth in fraud rates in the United States. According to a report released this year by Security.org 1 151 million Americans have fallen victim to credit card fraud.
65 percent of credit and credit card holders have been fraud victims at some point in their lives, up from 58 percent last year. This equates to about 151 million Americans.
An increasing number of Americans have been victimized multiple times: in 2022, 44 percent of credit card users reported having two or more fraudulent charges, compared to 35 percent in 2021
Credit Card fraud is a growing issue for both card holders and card issuing banks. The biggest under the radar cost to the consumer is the add on fraud crimes that happen following a credit card fraud instance. A growing number of credit card fraud victims become also victims of other identity theft-based crimes which can be financially devastating to card fraud victims according to SmartMetric.
“The need for a more secure credit and debit card is more needed today than ever before. That is why we have spent well over a decade in research and development to create a work anywhere at anytime biometric protected credit card," said SmartMetric’s President & CEO, Chaya Hendrick.
The SmartMetric biometric credit card is the only advanced biometric payments card product with an internal rechargeable battery that allows the card to be used in all card usage cases such as restaurants and ATM’s. Having its own power inside the card allows the SmartMetric biometric card to work prior to the card being inserted into a card reader.
The SmartMetric biometric fingerprint recognition technology built inside of the credit and debit card uses embedded biometric technology to positively recognize the card holder and then only after a positive fingerprint recognition, turn on the cards EMV contact and contactless payments chip.
According to an article published by Finder.com 2 the number of credit card accounts open in the United States is 564,500,000. This is an all-time high for the United States.
The average American owns three credit cards. 83% of Americans own at least one credit card. 14% of Americans own at least 10 credit cards.
To view the SmartMetric Biometric Card please follow this link - Video of the SmartMetric Biometric Card. To view the company website: http://www.smartmetric.com
1 2023 Credit Card Fraud Report | Security.org
2 2023 Credit card debt and spending statistics in the US | finder.com
Safe Harbor Statement: Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Also such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, among others, if we are unable to access the capital necessary to fund current operations or implement our plans for growth; changes in the competitive environment in our industry and the markets where we operate; our ability to access the capital markets; and other risks discussed in the Company's filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, which filings are available from the SEC. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Investors and security holders are urged to carefully review and consider each of SmartMetric Inc. public filings with the SEC, including but not limited to, if applicable, Annual Reports on Form 10-K, proxy statements, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20231206647713r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206647713/en/
SmartMetric, Inc.
Chaya Hendrick
Tel: (702) 990-3687
Mobile: (305) 607-3910 (Pacific Time)
ceo@smartmetric.com
http://www.smartmetric.com
Source: SmartMetric, Inc.
$BTZI - The Bitcoin ATM brings cryptocurrency to the masses. The device can be used to exchange cryptocurrencies, issue crypto debit cards, billing, advertising, event ticket sales, international cryptocurrency transfers, gift card sales, microloans and more.
BOTS, Inc. has partnered with MultiATM to bring this exciting product to the American consumer.
For more information about the Bitcoin ATM, please visit the link below:
https://uspto.report/patent/app/20190318326
https://bots.bz/projects-services/
$BMNR
"Looking at 2024, we remain focused on profitably mining Bitcoin and being good stewards of the company's capital. We are continuing to evaluate the strategic deployment of additional mining machines
$SUIC OTC team is harnessing the power of high technology that's reshaping the food industry and increasing food production, quality, and safety while reducing our carbon footprint.
https://finance.yahoo.com/news/suic-ihart-offers-high-tech-110000380.html
$INBS Leading Specialist Material Handling Company, Titan Cranes and Rigging Pty Ltd., Adopts Intelligent Fingerprinting Drug Screening System
https://www.globenewswire.com/news-release/2023/11/30/2788587/0/en/Leading-Specialist-Material-Handling-Company-Titan-Cranes-and-Rigging-Pty-Ltd-Adopts-Intelligent-Fingerprinting-Drug-Screening-System.html
$KNOS OTC - KRONOS ADVANCED TECHNOLOGIES, INC. announced that the Company will be offering expedited shipping and discounts on its line of Home, Schools, and Small Business Air Purifier products as well as cutting edge graphene face masks.
https://finance.yahoo.com/news/kronos-advanced-technologies-fda-cleared-101800500.html
$NBIO - Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier.
The patent allowance recognizes PTB's ability to act as a monotherapy, as well as its potential to act as a conjugate, bringing other therapies across the BBB.
https://finance.yahoo.com/news/nascent-biotech-granted-japanese-patent-130000461.html
$CDSG AUGER DRILL PROGRAM TO BEGIN ON TITAN PROPERTIES
Las Vegas, NV, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Titan Lithium Inc., (OTC Markets: CDSG) (the “Company” or “CDSG”) is pleased to provide an exploration update on the Titan Lithium Projects in Tanzania.
The Company has retained Dr. Joas Kabete as technical director of Kilimanjaro Lithium Ltd. to supervise an auger drilling program to better understand the geology of Titan 1. Commencement of drilling to begin this weekend at Titan 1 to a depth of 100 feet with a minimum of 5 drill holes.
At present, the lithium-in-soil anomaly at Titan 1 is the largest worldwide, covering over 40 square miles (110 square kilometers) of continuous lithium values averaging over 4,000 ppm and containing high-grade areas where lithium values returned up to 4.82% Li2O (22,400 ppm Li).
About the Company: China Dongsheng International Inc. (OTC Markets: CDSG), through its wholly owned subsidiary Titan Lithium, Inc., is a lithium explorer and developer with operations in Nevada, USA and The United Republic of Tanzania.
Contact:
Harp Sangha-Chairman
sanghaharp1964@gmail.com
+1-702-595-2247
http://www.titanlithiuminc.com
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission.
$DFCO Special Report - 11-22-23
https://vimeo.com/884201828/c566ad2487
$CDSG ANNOUNCES TRANSFER OF PROSPECTING LICENSES IN TANZANIA
Las Vegas, NV., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Titan Lithium Inc., (OTC Markets: CDSG) (the “Company” or “CDSG”) is pleased to announce it has completed the full transfer of 100% interest in the Titan 1 and Titan 2 Prospecting Licenses in Tanzania into the Company’s’ Kilimanjaro Lithium Ltd (“KLL”) subsidiary.
Mineral rights in Tanzania are held under a number of types of licenses granted under the country’s comprehensive Mining Act. Exploration projects are held by a Prospecting License (“PL”) which allows the holder to conduct a wide range of exploration work until such a time as a mining license is required for exploitation.
The vendor completed the transfer of 100% of the two Prospecting Licenses for Titan 1 and Titan 2, PL 12353/2023 and PL 12338/2023, into KLL on November 14, 2023. The Prospecting Licenses that were transferred were duly recorded pursuant to section 123(1) of the Mining Act in the central register on November 16, 2023. The licenses will be available to view on the company’s website on the “About Us” tab .
These two PLs are considered prospective to the discovery of sediment hosted lithium style mineralization within a country rich in mineral resources. Tanzania is endowed with many types of minerals including gold, iron ore, nickel, copper, cobalt, gemstones, industrial minerals as well as rare earth minerals.
Tanzania is the fourth largest gold producer in Africa and home to advanced critical mineral projects such graphite, lithium and the high-grade nickel-copper-cobalt Kabanga deposit. Earlier this year, under a Presidential plan to fast track such deposits, Tanzania signed agreements worth $667 million for graphite and rare earth projects with several Australian Mining firms. As well, in February 2023, EV maker Tesla signed an agreement under which it will purchase between 17,500 to 35,000 tons per annum of Anode Active Material (AAM) from a producer in Tanzania
“Working closely with the vendor we are very pleased to have the licenses fully transferred”, commented Chairman Harp Sangha. “Our next steps will include the commencement of work that will include a strategic drill campaign designed to produce a maiden mineral resource that we hope will elevate the projects significantly.”
About the Company: China Dongsheng International Inc. (OTC Markets: CDSG), through its wholly owned subsidiary Titan Lithium, Inc., is a lithium explorer and developer with operations in Nevada, USA, and The United Republic of Tanzania.
Contact:
Harp Sangha-Chairman
Sanghaharp1964@gmail.com
+1-702-595-2247
http://www.titanlithiuminc.com
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors, or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission.
$RGBP News: Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments
SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing several candidates it has selected a Contract Research Organization (CRO) to perform the next set of experiments to elucidate the effectiveness of the Company's DuraCAR cells.
The Company is preparing a series of in vitro studies to test its DuraCAR cells in both immunosuppressive and in tumor-killing experiments. The experiments to explore whether these cells have an immunosuppressive effect include mixing the DuraCAR cells with activated immune cells that are designed to kill target tumor cells and to determine if these cells suppress this killing. In addition, the same experiments will be able to determine if the DuraCAR cells have a direct effect on killing tumors cells.
"We have designed a set of sophisticated experiments that test two hypotheses" says Dr. David Koos, Chairman and CEO of the company. "We have selected a CRO with excellent credentials and we expect the results to lay a clear path forward for this program."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION:
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: david.koos@regenbiopharmainc.com or david.koos@regenbiopharma.com
Twitter (now X): https://twitter.com/TheRegenBio
https://c212.net/c/img/favicon.png?sn=LN70703&sd=2023-11-16 View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-selects-contract-research-organization-to-assist-in-duracar-experiments-301989889.html
SOURCE Regen BioPharma Inc.
Amazing product with multiple applications very tightly held and could move $GEVI - Report and disclosures: https://us7.campaign-archive.com/?e=[UNIQID]&u=89b57034da8c35f61c7227a1d&id=d7d8218c55
$PSLV Physical Silver is on Breaking out on new CPI inflation Data